British scientists have created a groundbreaking machine that recycles blood lost in operations.
The invention will allow Jehovah’s Witnesses to have major surgery because it rules out the need for blood transfusions, which their faith forbids.
The technology could also save the NHS millions by reducing the demand for donated blood.
The Hemosep filtering machine was used recently on Jehovah’s Witness Julie Penoyer, 50. Doctors told the freelance translator she needed to have part of her aorta – the largest blood vessel in the body – replaced because it could burst at any time, killing her.
She suffers from a rare inherited condition called Marfan Syndrome, which makes her cartilage highly stretchy, meaning the walls of the top of her aorta were dangerously thin.
But she said she would agree to surgery only if she could have the operation without a transfusion. Jehovah’s Witnesses believe it is against God’s will to ‘ingest blood’ in any way.
The team at the Trent Cardiac Centre in Nottingham then mentioned the Hemosep machine.
Unlike other blood recovery devices, it enables the collection not only of red blood cells but also of crucial cells and enzymes that help it to clot, meaning Mrs Penoyer could have the operation without receiving any blood products.
She underwent the seven-hour operation in late January and is now recovering well after spending just 13 days in hospital.
Last night she said: ‘People tell me they can’t believe I’ve recently had heart surgery.
At last I can breathe properly again.’
During the operation Mrs Penoyer lost more than two pints of blood.
But this was pumped straight back into her body.
The machine works by filtering blood through a plastic membrane that captures vital red blood cells, clotting cells called platelets and enzymes called clotting factors.
Jonathan Bain, who operated the machine, explained: ‘We had to have everything connected in one continuous loop, so at no point would the blood have left her body’s circulation. We went to great lengths to make sure the loop was not broken.’ He added: ‘This was a life-saving operation because the danger was that her aorta could have ruptured at any time. That would have been catastrophic.’ But it would have been nearly impossible to save her life after a rupture without resorting to a blood transfusion, he added.
The machine was the brainchild of Terry Gourlay, professor of biomedical engineering at Strathclyde University in Glasgow. He took his idea to Brightwake, a Midlands-based firm, which makes wound dressings and other high-tech medical products. Founder Steve Cotton said: ‘It shows what is possible with a bit of British ingenuity.’ He has calculated the device could save the NHS more than £10 million a year by reducing the demand for donated blood. Read more: http://www.dailymail.co.uk/news/article-2614169/UK-blood-recycling-breakthrough-let-Jehovahs-Witnesses-major-surgery.html
This article has been copied below.
Origin: Nachrichtenquelle: PR Newswire (engl.) 14.04.2014,16:53
- New Hemosep device enables patient to undergo open-heart surgery while upholding religious beliefs -
UK-based company reduces prototyping costs by 96% using Stratasys 3D printed parts MINNEAPOLIS and REHOVOT, Israel, April 14, 2014 /PRNewswire/ -- Stratasys Ltd. (Nasdaq: SSYS), a leading global provider of 3D printing and additive manufacturing solutions, today announced that Brightwake Ltd., has developed a revolutionary blood recycling machine, called the Hemosep, using Stratasys' Dimension 1200es 3D Printer.
The Hemosep recovers blood spilled during open heart and major trauma surgery, concentrating the blood cells ready for transfusion back into the patient.
This process, known as autotransfusion, reduces the volume of donor blood required and the problems associated with transfusion reaction. The prototype device features a number of Stratasys 3D printed parts, including the main filtration and cooling systems, enabling the Brightwake team to functionally test the system in its intended environment, before the final device is produced from metal.
The device has been awarded the CE mark and is attracting global interest from distributors and healthcare providers. "The Hemosep consists of a bag that uses chemical sponge technology and a mechanical agitator to concentrate blood sucked from a surgical site or drained from a heart-lung machine after surgery," says Steve Cotton, Brightwake's Director of Research and Development. "The cells are then returned to the patient via blood transfusion. In a climate of blood shortage, this recycling methodology has the potential to be a game-changer within the medical industry, saving the National Health Service millions."
Successful UK Trial Upholds Patient's Religious Beliefs Successful clinical trials of over 100 open-heart surgery operations in Turkey confirmed the Hemosep's ability to significantly reduce the need for blood transfusions, and further trials are now continuing in the UK. One of the first patients to benefit from the new Hemosep device is 50-year-old UK heart patient Julie Penoyer, who, as a Jehovah's Witness, requested not to receive donated blood products.
Because the device captures, cleans and puts back lost blood lost during an operation, Hemosep was the perfect solution for her. The success of Hemosep's use during Mrs. Penoyer's operation presents new possibilities for patients across the globe, whose religious beliefs mean that receiving donated blood is not an option.
Prototyping Costs Slashed by 96% and Lead-Times Eliminated Thanks to In-house Production For Brightwake, with medical device production demanding extremely accurate parts, capable of enduring the stress of functional and safety tests, the company's use of 3D printing has presented significant cost- and time-saving benefits. "Previously we had to outsource the production of these parts which took around three weeks per part," explains Cotton. "Now we're 3D printing superior strength parts overnight, cutting our prototyping costs by 96% and saving more than £1,000 for each 3D printed model. "3D printing has not only enabled us to cut our own costs, it has also been crucial in actually getting a functional device to clinical trials," he adds. "The ability to 3D print parts that look, feel and perform like the final product, on-the-fly, is the future of medical device manufacturing."
Originating in Nottingham's traditional textiles industry, Brightwake is a family-run creative development, engineering, production and research company specializing in innovative manufacturing solutions. With nearly 35 years' experience, Brightwake has now extended its expertise into the medical field, starting with the production of wound dressing for the UK's National Health Service (NHS).
Armed with its Stratasys' Dimension 1200es 3D Printer from UK reseller Stanford Marsh, the company now has the in-house capability to extend its medical device manufacturing program beyond the Hemosep. "In the fast-paced, competitive medical device industry, we are seeing more and more of our customers use 3D printing to bring their products to market more efficiently and cost-effectively," reports Andy Middleton, Senior Vice President and General Manager EMEA. "The ability to turn ideas into functional products quickly is something that in the long-term we believe will improve the quality of care, and in some cases, save lives."
Stratasys Ltd. (Nasdaq: SSYS), headquartered in Minneapolis, Minn. and Rehovot, Israel, is a leading global provider of 3D printing and additive manufacturing solutions.
The company's patented FDM® and PolyJet™ 3D Printing technologies produce prototypes and manufactured goods directly from 3D CAD files or other 3D content. Systems include 3D printers for idea development, prototyping and direct digital manufacturing. Stratasys subsidiaries include MakerBot and Solidscape, and the company operates the RedEye digital-manufacturing service.
Stratasys has more than 1,800 employees, holds over 550 granted or pending additive manufacturing patents globally, and has received more than 20 awards for its technology and leadership. Online at: www.stratasys.com
Cautionary Statement Regarding Forward-Looking Statements Certain information included or incorporated by reference in this press may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified.
These forward-looking statements may include, but are not limited to, statements relating to the company's objectives, plans and strategies, statements regarding the performance of our products, statements that contain projections of results of operations or of financial condition (including, with respect to the MakerBot acquisition) and all statements (other than statements of historical facts) that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. The company has based these forward-looking statements on assumptions and assessments made by its management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things: the company's ability to efficiently and successfully integrate the operations of Stratasys, Inc. and Objet Ltd. after their merger as well as MakerBot after its acquisition and to successfully put in place and execute an effective post-merger integration plans; the overall global economic environment; the impact of competition and new technologies; general market, political and economic conditions in the countries in which the company operates; projected capital expenditures and liquidity; changes in the company's strategy; government regulations and approvals; changes in customers' budgeting priorities; litigation and regulatory proceedings; and those factors referred to under "Risk Factors", "Information on the Company", "Operating and Financial Review and Prospects", and generally in the company's annual report on Form 20-F for the year ended December 31, 2013 filed with the U.S. Securities and Exchange Commission and in other reports that the company has filed with the SEC. Readers are urged to carefully review and consider the various disclosures made in the company's SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects.
Any forward-looking statements in this press release are made as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
:
